Samsung Biologics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
| 207940 Stock | 934,000 2,000 0.21% |
About 55% of Samsung Biologics' investor base is interested to short. The analysis of current outlook of investing in Samsung Biologics Co suggests that many traders are impartial regarding Samsung Biologics' prospects. The current market sentiment, together with Samsung Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Samsung Biologics stock news signals to limit their universe of possible portfolio assets.
Samsung |
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Marketscreener.com
Read at news.google.com
 |
Samsung Biologics Fundamental Analysis
We analyze Samsung Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Samsung Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Samsung Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Samsung Biologics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Samsung Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Samsung Biologics stock to make a market-neutral strategy. Peer analysis of Samsung Biologics could also be used in its relative valuation, which is a method of valuing Samsung Biologics by comparing valuation metrics with similar companies.
Peers
Samsung Biologics Related Equities
| 026890 | Digital Power | 1.69 | ||||
| 286940 | Lotte Data | 0.75 | ||||
| 054040 | Korea Computer | 0.37 | ||||
| 035510 | Shinsegae Information | 0.11 | ||||
| 094940 | Puloon Technology | 1.19 | ||||
| 048530 | INtRON Biotechnology | 1.58 | ||||
| 019540 | Ilji Technology | 1.97 |
Complementary Tools for Samsung Stock analysis
When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |